Connective Tissue Growth Factor at the American Society of Nephrology meeting

Home > News & Events > Press Releases > November 12, 2003


	Press Releases

	Events

	FibroGen News by Email!

	Publications

Press Release

FibroGen Announces Abstracts on Connective Tissue Growth Factor to be Presented at the 2003 Meeting of the American Society of Nephrology

South San Francisco, Calif. - November 12, 2003 - FibroGen, Inc., today announced that multiple abstracts on the Company's research related to Connective Tissue Growth Factor will be presented at Renal Week 2003, the annual meeting of the American Society of Nephrology, being held November 12th-17th in San Diego, CA. The abstracts to be presented include the following:

Title: Human Urinary CTGF (CCN2) as a Predictor of Progression of Chronic Renal Diseases
Authors: Yasuhiko Ito, Hirotake Kasuga, Fujita Yoshirou, Yukio Yuzawa, Seiichi Matsuo, Noelynn Oliver, William Usinger, Stephen Weitz, Evelene Lomongsod
Date/Time: Friday, November 14, 2003 - 10:00 AM
Session Info: Poster: Renal Pathology and Laboratory Medicine (10:00 AM - 12:00 PM)
Poster Board Number: F-PO412
Title: Connective Tissue Growth Factor (CTGF): A Biomarker of Chronic Allograft Nephropathy (CAN)
Authors: Roslyn B. Mannon, Orlena Cheng, Xiaojie Zhang, Steven Hoffmann, William Usinger, Allan Kirk
Date/Time: Friday, November 14, 2003 - 4:30 PM
Session Info: Free Communication: Transplantation: Experimental (4:00 PM - 6:00 PM)
Title: TGF-beta-2 Binds CTGF Specifically and Is Inhibited by a CTGF Neutralizing Antibody
Authors: William R. Usinger, Robert Berg, Leon Z. Xu, Stephen L. Weitz
Date/Time: Saturday, November 15, 2003 - 10:00 AM
Session Info: Poster: Growth Factors and Fibrosis I (10:00 AM - 12:00 PM)
Poster Board Number: SA-PO354

About FibroGen, Inc.

FibroGen, Inc., is a privately held biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics and biomaterials to address unmet needs in the medical, pharmaceutical, and consumer markets. FibroGen's therapeutic target areas include fibrosis, anemia, and ischemia, and the Company develops and manufactures recombinant human collagen and gelatin biomaterials.

For more information about FibroGen, Inc., please visit www.fibrogen.com